关键词：多发性骨髓瘤；白血细胞；产生抗体；对抗感染；细菌攻击
摘 要：Multiple myeloma is one of the most common types of cancer that affects plasma cells, a type of white blood cells. It is the cancer of plasma cells. The primary function of plasma cells is to produce antibodies to combat infections and germ attacks. In multiple myeloma, the plasma cells become malignant and undergo overproduction of a defective protein, which accumulates in the bone marrow forming multiple tumors. This abnormal protein can also cause kidney problems in patients. According to the Multiple Myeloma Research Foundation, the disease has been classified into three distinct stages: stages I, II, and III. Some of the prominent symptoms of multiple myeloma are pain in the bone, fracture of the bone, vulnerability to infections, increased restlessness, problems associated with kidneys and urination, fatigue, increased thirst, loss of appetite, and loss of weight. The formation of bone lesions, low blood count, hypercalcemia, and impairment of kidney function are the other common symptoms of the disease. Multiple myeloma can be diagnosed by a series of tests such as blood test, urine test, and bone marrow biopsy. Some of the other tests to diagnose multiple myeloma are an Xray, MRI scan, CT scan, and PET scan. Genomic testing is also carried out to confirm the presence of multiple myeloma in suspected patients.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Product Profiles

04.1.1 Pomalyst/Imnovid

04.1.2 Revlimid

04.1.3 Zometa

04.1.4 Doxil/Caelyx

04.1.5 Thalomid/Thalidomide Celgene

04.1.6 Kyprolis

04.1.7 Mozobil

04.1.8 Velcade

05. Market Research Methodology

05.1 Market Research Process

05.2 Research Methodology

06. Introduction

07. Disease Overview

07.1 Understanding Multiple Myeloma

07.2 Pathophysiology

07.3 Epidemiology

07.4 Diagnosis

07.5 Staging

07.6 Management

07.7 Economic Burden

08. Market Landscape

08.1 Market Overview

08.2 Market Size and Forecast

08.3 Five Forces Analysis

09. Market Segmentation by Route of

Administration

09.1 Global Multiple Myeloma Drugs Market

Segmentation by Route of Administration

09.2 Oral

09.3 Parenteral

10. Market Segmentation by Dosage Form

10.1 Solid

10.2 Liquid

11. Geographical Segmentation

11.1 Global Multiple Myeloma Drugs Market by

Geographical Segmentation 2014

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Pipeline Portfolio

20. Vendor Landscape

20.1 Competitive Scenario

20.1.1 Key News

20.1.2 Mergers and Acquisitions

20.2 Market Share Analysis 2014

20.2.1 Celgene

20.2.2 Johnson & Johnson

20.2.3 Novartis

20.2.4 Onyx Pharmaceuticals

20.2.5 Sanofi

20.2.6 Takeda Pharmaceutical

20.3 Other Current and Future Prominent Vendors

21. Key Vendor Analysis

21.1 Celgene

21.1.1 Key Facts

21.1.2 Business Overview

21.1.3 Business Strategy

21.1.4 Business Segmentation by Revenue

21.1.5 Revenue by Geographical Segmentation

21.1.6 Key Information

21.1.7 SWOT Analysis

21.2 Johnson & Johnson

21.2.1 Key Facts

21.2.2 Business Overview

21.2.3 Business Segmentation by Revenue 2013

21.2.4 Business Segmentation by Revenue 2012 and 2013

21.2.5 Geographical Segmentation by Revenue 2013

21.2.6 Business Strategy

21.2.7 Recent Developments

21.2.8 SWOT Analysis

21.3 Novartis

21.3.1 Key Facts

21.3.2 Business Description

21.3.3 Business Segmentation

21.3.4 Revenue by Business Segmentation

21.3.5 Revenue by Business Segmentation 2012 and 2013

21.3.6 Revenue by Geographical Segmentation

21.3.7 Business Strategy

21.3.8 Key Developments

21.3.9 SWOT Analysis

21.4 Onyx Pharmaceuticals

21.4.1 Key Facts

21.4.2 Business Overview

21.4.3 Marketed Products

21.4.4 Geographical Segmentation

21.4.5 Business Strategy

21.4.6 Recent Developments

21.4.7 SWOT Analysis

21.5 Sanofi

21.5.1 Key Facts

21.5.2 Business Overview

21.5.3 Business Segmentation by Revenue 2013

21.5.4 Business Segmentation by Revenue 2012 and 2013

21.5.5 Geographical Segmentation by Revenue

21.5.6 Business Strategy

21.5.7 Key Developments

21.5.8 SWOT Analysis

21.6 Takeda Pharmaceutical

21.6.1 Key Facts

21.6.2 Business Overview

21.6.3 Business Segmentation by Revenue 2013

21.6.4 Business Segmentation by Revenue 2013

21.6.5 Geographical Segmentation by Revenue 2013

21.6.6 Business Strategy

21.6.7 Recent Developments

21.6.8 SWOT Analysis

22. Other Reports in this Series